# Systemic anti-cancer therapy for advanced non-small-cell lung cancer

## Squamous non-small cell lung cancer, KRAS G12C positive, PD‑L1 50% or higher

Initial recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770) (only if urgent clinical intervention is needed) or
* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta705).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781) (available through the Cancer Drugs Fund).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770) and who have disease progression after treatment with docetaxel, the only recommended treatment option is the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781) (available through the Cancer Drugs Fund; NHS England policy).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab with carboplatin and paclitaxel](https://www.nice.org.uk/guidance/ta770) and who have disease progression after treatment in line with the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781), the only recommended treatment option is docetaxel.

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or [atezolizumab](https://www.nice.org.uk/guidance/ta705), recommended treatment options are:

* platinum doublet chemotherapy or
* the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781) (available through the Cancer Drugs Fund).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or [atezolizumab](https://www.nice.org.uk/guidance/ta705) and who have disease progression after treatment with platinum doublet chemotherapy, recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781) (available through the Cancer Drugs Fund).

For people who have had platinum doublet chemotherapy and who have disease progression after follow-up treatment with docetaxel, the only recommended treatment option is the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781) (available through the Cancer Drugs Fund; NHS England policy).

For people who have had platinum doublet chemotherapy and who have disease progression after follow-up treatment in line with the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781), the only recommended treatment option is docetaxel.

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or [atezolizumab](https://www.nice.org.uk/guidance/ta705) and who have disease progression after treatment in line with the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781), recommended treatment options are:

* docetaxel or
* platinum doublet chemotherapy.

For people who have had treatment in line with the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781) and who have disease progression after follow-up treatment with docetaxel, the only recommended treatment option is platinum doublet chemotherapy.

For people who have had treatment in line with the [NICE technology appraisal guidance on sotorasib](https://www.nice.org.uk/guidance/ta781) and who have disease progression after follow-up treatment with platinum doublet chemotherapy, the only recommended treatment option is docetaxel.